Table 1.
Patient Sample Diagnostics
| Sample | Sex | Age | Disease | ISS Stage | CTG | FISH | Prior Lines | LEN Ref | BZ Ref | CZ Ref | POM Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||
| MM68 | M | 74 | MM | ND | Complex karyotype | + IgH; + 1q; trisomy 3, 7; monosomy 13 | 5 | Y | Y | Y | N |
|
|
|||||||||||
| MM65 | M | 80 | sPCL | ND | Complex karyotype | del 1p; + 1q; + 14q; trisomy 9 | 5 | Y | Y | N | Y |
|
|
|||||||||||
| MM64 | F | 68 | MM | 1 | 46, XX | Negative | 1 | N | N | N | N |
|
|
|||||||||||
| MM74 | M | 50 | MM | 1 | 46, XY | t(4;14); + IgH; del 13q; trisomy 3; monosomy 7, 13 | 0 | N | N | N | N |
|
|
|||||||||||
| MM61 | M | 63 | pPCL | 3 | t(2;8) t(11;14) |
t(11;14) | 0 | N | N | N | N |
|
|
|||||||||||
| MM66 | M | 60 | MM | ND | Complex karyotype | + IgH; tetrasomy 1; trisomy 3, 7, 9; del 1p; del 13 | 4 | Y | Y | N | Y |
|
|
|||||||||||
| MM62 | F | 69 | MM | 3 | del (16) | t(4;14); + IgH; del 13 | 0 | N | N | N | N |
|
|
|||||||||||
| MM63 | F | 52 | MM | 1 | 46, XX | + IgH; + 1q; monosomy 13, 16 | 0 | N | N | N | N |
|
|
|||||||||||
| MM54-2 | M | 68 | MM | 1 | Complex karyotype | +7, 9, 11 | 2 | N | N | N | N |
Abbreviations: MM, multiple myeloma; sPCL, secondary plasma cell leukemia; pPCL, primary plasma cell leukemia; ND, not determined; CTG, cytogenetics; +, gain of; del, deletion of; LEN, lenalidomide; BZ, bortezomib; CZ, carfilzomib; POM, pomalidomide; Ref, refractory; Y, yes; N, no